Effects of Antifungal Agents Alone and in Combination Against Candida glabrata Strains Susceptible or Resistant to Fluconazole

Mycopathologia

Volumn 174, Issue 3, 2012, Pages 215-221

  Alves, Izabel Almeida ^a   Bandeira, Laíssa Arévalo ^a   Mario, Débora Alves Nunes ^a   Denardi, Laura Bedin ^a   Neves, Louise Vignoles ^a   Santurio, Janio Morais ^a   Alves, Sydney Hartz ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Antifungal drug combination; Candida glabrata; Resistance

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA GLABRATA; CANDIDIASIS; DRUG EFFECT; DRUG INTERACTION; HUMAN; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; DRUG INTERACTIONS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS;

CANDIDA; CANDIDA GLABRATA;

EID: 84864286193     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-012-9538-7     Document Type: Article

References (31)

1. Arai R, Sugita T, Nishikawa A. Reassessment of the in vitro synergistic effect of fluconazole with the non-steroidal anti-inflammatory agent ibuprofen against Candida albicans. Mycoses. 2005; 2005(48): 38-41.
2. Baltch AL, Bopp LH, Smith RP, Ritz WJ, Michelsen PB. AntiCandidal effects of voriconazole and caspofungin, singly and in combination, against Candidaglabrata, extracellularly and intracellularly in granulocyte-macrophage colony stimulating factor (GM-CSF)-activated human monocytes. J Antimicrob Chemother. 2008; 62: 1285-90.
3. Barchiesi F, Gallo D, Caselli F, Di Francesco LF, Arzeni D, Giacometti A, Scalise G. In vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. J Antimicrob Chemother. 1999; 44: 65-70.
4. Barchiesi F, Spreghini E, Maracci M, Fothergill AW, Badassarri I, Rinaldi MG, Scalise G. In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. Antimicrob Agents Chemother. 2004; 48: 3317-22.
5. Barchiesi F, Spreghini E, Fothergill AW, Arzeni D, Graganti G, Giannini D, Rinaldi MG, Scalise G. Caspofungin in combination with amphotericin B against Candida glabrata. Antimicrob Agents Chemother. 2005; 49: 2546-9.
6. Bennett JE, Izumikawa K, Marr KA. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother. 2004; 48: 1773-7.
7. Block E, Bennett JE. The combined effect of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis. Proc Soc Exp Biol Med. 1973; 142: 476-80.
8. Cantón E, Pemán J, Gobernado M, Viudes A, Ana Espinel-Ingroff A. Synergistic Activities of Fluconazole and Voriconazole with Terbinafine against Four Candida Species Determined by Checkerboard, Time-Kill, and Etest Methods. Antimicrob Agents Chemother. 2005; 49: 1593-6.
9. rd ed. Approved standard M27-A3. 2008; Wayne, PA.
10. Colombo AL, Nucci M, Park BJ, Nouer AS, Arthington-Skaggs B, Matta DA, Warnock D, Morgan J. The Brazilian Network Candidemia Study. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol. 2006; 44: 2816-23.
11. Dumainn V, Eyrolle L, Baixench MT, Paugam A, Larousserie F, Padoin C, Tod M, Salmon D. Successful treatment of prosthetic knee Candida glabrata infection with caspofungin combined with flucytosine. Int J Antimicrob Chemother. 2008; 31: 398-9.
12. Denning DW, Baily GG, Hood SV. Azole resistance in Candida. Eur J Clin Microbiol Infect Dis. 1997; 16: 261-80.
13. Fekete-Forgács K, Gyurc L, Lenkey B. Changes of virulence factors accompanying the phenomenon of induced fluconazole resistance in Candida albicans. Mycoses. 1999; 43: 273-9.
14. Garcia-Effron G, Mellado E, Gomez-Lopez A, Alcazar-Fuolli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Differences in interactions between azole drugs related to modifications in the 14-sterol demethylase gene (cyp51a) of Aspergillus fumigatus. Antimicrob Agents Chemother. 2005; 49: 2119-21.
15. Ghannoum MA, Isham N. Abstr. 29th Annu. Meet. Eur. Group Blood and Marrow Transplant. 2003; Abstr. 671.
16. Hossain MA, Reyes GH, Long LA, Mukherjee PK, Ghannoum MA. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J Antimicrob Chemother. 2003; 51: 1427-9.
17. Johnson MD, Macdougall C, Ostrosky L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother. 2004; 48: 693-715.
18. Lewis RE, Diekema DJ, Messes SA, Pfaller MA, Klepser ME. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother. 2002; 49: 345-51.
19. Odds FC. Interactions among amphotericin b, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother. 1982; 22: 763-70.
20. Oz Y, Akşit F, Kiraz N, Kiremitçi A. In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates. Mikrobiyol Bul. 2008; 42: 149-55.
21. Pina-Vaz C, Sansonetty F, Rodrigues AG, Martinez-De-Oliveira J, Fonseca AF, Mårdh PA. Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species. J Med Microbiol. 2000; 49: 831-40.
22. Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, Diekema DJ. In vitro activities of voriconazole, posaconazole, and fluconazole against 4, 169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis. 2004; 48: 201-5.
23. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007; 20: 133-63.
24. Polak A. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy. 1987; 33: 381-95.
25. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli S, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005; 49: 668-79.
26. Scheid LA, Mario DAN, Kubiça TF, Santurio JM, Alves SH. In vitro activities of antifungal agents alone and in combination against fluconazole-susceptible and -resistant strains of Candida dubliniensis. Braz J Infect Dis. 2012; 16(78): 81.
27. Siau H, Kerridge D. The effect of antifungal drugs in combination on the growth of Candida glabrata in solid and liquid media. J Antimicrob Chemother. 1998; 41: 357-66.
28. Silva EG, Paula CR, Dias AL, Chan MR, Ruiz LD, Gambale V, Prates R, Ribeiro MS. Combination efficacy of voriconazole and amphotericin b in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans. Mycopathologia. 2010; 24: 31-6.
29. Tobudic S, Kratzer C, Lassnigg A, Graninger W, Prestrl E. In vitro activity of antifungal combinations against Candida albicans biofilms. J Antimicrob Chemother. 2010; 65: 271-4.
30. White DJ, Habib AR, Vanthuyne A, Langford S, Symonds M. Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections. Sex Transm Inf. 2001; 77: 212-3.
31. Vazquez JA. Combination antifungal therapy against Candida species: the new frontier-are we there yet? Med Mycol. 2003; 41: 355-68.